BioCurity Pharmaceuticals
Regulation Crowdfunding offering on StartEngine
$711,340
of $1.07M goal
66.5% funded
About the offering
BioCurity is a clinical stage biopharmaceutical company with a mission to materially improve and transform radiation therapy for cancer patients. Our proprietary technology is designed to prevent or mitigate damage to skin and normal internal tissue during radiation therapy without impairing the effectiveness of the radiation treatment on the patient’s cancer cells. The proposed drugs generated from BioCurity’s proprietary technology have been preclinically tested for multiple cancers including breast, lung, head and neck, prostate and colorectal cancer. The delivery system of the proposed drug includes a topical for the skin to prevent or mitigate skin damage (radiation dermatitis) and an intravenous (IV) formulation for internal tissue protection from radiation damage.
FAQ
How much has BioCurity Pharmaceuticals raised?
BioCurity Pharmaceuticals has raised $711,340 of a $1.07M goal.
Where is BioCurity Pharmaceuticals's campaign listed?
The offering is listed on StartEngine, an SEC-registered Reg CF intermediary.
What are the terms of BioCurity Pharmaceuticals's raise?
Preferred Stock, $34M cap, $4.25/share.
When does BioCurity Pharmaceuticals's offering close?
The stated close date is Jun 29, 2020.